Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201520
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fröberg, Gabrielle | - |
dc.contributor.author | Maurer, Florian P. | - |
dc.contributor.author | Chryssanthou, Erja | - |
dc.contributor.author | Fernström, Louise | - |
dc.contributor.author | Benmansour, Hanaa | - |
dc.contributor.author | Boarbi, Samira | - |
dc.contributor.author | Mengshoel, Anne Torunn | - |
dc.contributor.author | Keller, Peter M. | - |
dc.contributor.author | Viveiros, Miguel | - |
dc.contributor.author | Machado, Diana | - |
dc.contributor.author | Fitzgibbon, Margaret M. | - |
dc.contributor.author | Mok, Simone | - |
dc.contributor.author | Werngren, Jim | - |
dc.contributor.author | Cirillo, Daniela Maria | - |
dc.contributor.author | Alcaide, Fernando | - |
dc.contributor.author | Hyyryläinen, Hanne-Leena | - |
dc.contributor.author | Aubry, Alexandra | - |
dc.contributor.author | Andres, Sönke | - |
dc.contributor.author | Nadarajan, Darshaalini | - |
dc.contributor.author | Svensson, Erik | - |
dc.contributor.author | Turnidge, John | - |
dc.contributor.author | Giske, Christian G. | - |
dc.contributor.author | Kahlmeter, Gunnar | - |
dc.contributor.author | Cambau, Emmanuelle | - |
dc.contributor.author | van Ingen, Jakko | - |
dc.contributor.author | Schön, Thomas | - |
dc.contributor.author | EUCAST AMST | - |
dc.contributor.author | ESCMYC study groups | - |
dc.date.accessioned | 2023-08-25T11:53:59Z | - |
dc.date.available | 2023-08-25T11:53:59Z | - |
dc.date.issued | 2023-02-20 | - |
dc.identifier.issn | 1198-743X | - |
dc.identifier.uri | http://hdl.handle.net/2445/201520 | - |
dc.description.abstract | Objective: For non-tuberculous mycobacteria (NTM), minimum inhibitory concentration (MIC) distributions of wild-type isolates have not been systematically evaluated despite their importance for establishing antimicrobial susceptibility testing (AST) breakpoints. Methods: We gathered MIC distributions for drugs used against the Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) obtained by commercial broth microdilution (SLOMYCOI and RAPMYCOI) from 12 laboratories. Epidemiological cut-off values (ECOFFs) and tentative ECOFFs (TECOFFs) were determined by EUCAST methodology including quality control (QC) strains. Results The clarithromycin ECOFF was 16 mg/L for M. avium (n=1271) whereas TECOFFs were 8 mg/L for M. intracellulare (n=415) and 1 mg/L for MAB (n=1014) confirmed by analysing MAB subspecies without inducible macrolide resistance (n=235). For amikacin, the ECOFFs were 64 mg/L for MAC and MAB. For moxifloxacin, the WT spanned >8 mg/L for both MAC and MAB. For linezolid, the ECOFF and TECOFF were 64 mg/L for M. avium and M. intracellulare, respectively. Current CLSI breakpoints for amikacin (16 mg/L), moxifloxacin (1 mg/L) and linezolid (8 mg/L) divided the corresponding WT distributions. For QC M. avium and M. peregrinum, ≥95% of MIC values were well within recommended QC ranges. Conclusion : As a first step towards clinical breakpoints for NTM, (T)ECOFFs were defined for several antimicrobials against MAC and MAB. Broad wild-type MIC distributions indicate a need for further method refinement which is now under development within the EUCAST subcommittee for anti-mycobacterial drug susceptibility testing. In addition, we showed that several CLSI NTM breakpoints are not consistent in relation to the (T)ECOFFs. | - |
dc.format.extent | 7 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | European Society of Clinical Microbiology and Infectious Diseases | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.cmi.2023.02.007 | - |
dc.relation.ispartof | Clinical Microbiology and Infection, 2023, vol. 29, p. 758-764 | - |
dc.relation.uri | https://doi.org/10.1016/j.cmi.2023.02.007 | - |
dc.rights | cc by (c) Fröberg, Gabrielle et al., 2023 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Medicaments antibacterians | - |
dc.subject.classification | Resistència als medicaments | - |
dc.subject.classification | Micobacteris | - |
dc.subject.other | Antibacterial agents | - |
dc.subject.other | Drug resistance | - |
dc.subject.other | Mycobacteria | - |
dc.title | Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 732562 | - |
dc.date.updated | 2023-08-25T11:53:59Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36813087 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
732562.pdf | 1.11 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License